Precision BioSciences (NASDAQ:DTIL) Earns "Sell (E+)" Rating from Weiss Ratings

Key Points

• Weiss Ratings has reiterated a "sell (E+)" rating for Precision BioSciences (NASDAQ:DTIL) based on its latest research report, indicating a negative outlook for the stock.
• In its most recent earnings report, Precision BioSciences reported a loss of ($2.13) earnings per share, significantly missing the consensus estimate of ($0.09) and generating just $0.02 million in revenue.
• Currently, approximately 37.99% of Precision BioSciences' stock is owned by institutional investors, which includes recent increased stakes from several hedge funds.

Precision BioSciences (NASDAQ:DTIL - Get Free Report)'s stock had its "sell (e+)" rating reiterated by research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Precision BioSciences Price Performance

Shares of DTIL stock opened at $5.70 on Wednesday. Precision BioSciences has a 52 week low of $3.61 and a 52 week high of $9.27. The stock has a market capitalization of $67.20 million, a PE ratio of -0.65 and a beta of 1.72. The company has a debt-to-equity ratio of 0.66, a quick ratio of 5.18 and a current ratio of 5.18. The stock's fifty day moving average is $4.94 and its 200-day moving average is $4.88.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($2.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($2.04). Precision BioSciences had a negative return on equity of 176.47% and a negative net margin of 6,205.79%.The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $6.27 million. Equities research analysts expect that Precision BioSciences will post -1.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC lifted its stake in shares of Precision BioSciences by 5.5% in the 2nd quarter. Geode Capital Management LLC now owns 77,712 shares of the company's stock valued at $326,000 after purchasing an additional 4,025 shares during the period. Miller Financial Services LLC acquired a new position in Precision BioSciences in the first quarter valued at about $48,000. Tejara Capital Ltd lifted its stake in Precision BioSciences by 185.2% in the first quarter. Tejara Capital Ltd now owns 60,427 shares of the company's stock valued at $288,000 after buying an additional 39,242 shares during the period. Bridgeway Capital Management LLC bought a new position in Precision BioSciences during the second quarter worth about $260,000. Finally, Corient Private Wealth LLC acquired a new position in shares of Precision BioSciences during the 2nd quarter worth about $425,000. 37.99% of the stock is currently owned by institutional investors.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.